Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
22 results
D1.452 - Remission as a therapeutic goal in chronic rhinosinusitis with nasal polyps treated with Dupilumab: a multicenter real-world study
D1.453 - Pregnancy in Eosinophilic Granulomatosis with Polyangiitis (EGPA): a case report and literature review
D1.455 - Dupilumab Efficacy in Unified Airways Disease: Pooled Analysis of Patients With Chronic Rhinosinusitis With Nasal Polyps/Allergic Fungal Rhinosinusitis With Coexisting Asthma in Ph3/4 Clinical Trials
D1.457 - Clinical and immune profile of newborns born to mothers with inflammatory diseases exposed to biological drugs during pregnancy
D1.460 - Diagnostic Opportunities in Type 2 Inflammations - A Machine-Learning Approach: EAACI Task Force Update
D1.461 - Dupilumab as a Steroid-Sparing Treatment Option for Pemphigus Vulgaris: A Case Series from a Tertiary Centre
D1.463 - Real-World Transition from Reference Omalizumab to Biosimilar Omlyclo in Patients with Chronic Urticaria: A Single-Center Descriptive Study
D1.451 - Adherence and persistence to biological treatments in patients with CRSwNP and comorbid asthma
D1.456 - Integrated Analysis of Nemolizumab Immunogenicity Indicates No Effect on the Overall Benefit-Risk Profile of Nemolizumab in Patients with Atopic Dermatitis or with Prurigo Nodularis
D1.372 - Transition to SCIG as an Alternative in Patients with Cytokine Storm from IVIG
D1.374 - Genetic susceptibility to radiocontrast media-induced anaphylaxis: A microarray gene chip study in a Korean population
D1.365 - Long-term course of NSAID tolerance in patients with cross-hypersensitivity presenting with respiratory symptoms
D1.366 - “Intense peri-vaginal itching as a lone symptom”: a unique presentation of Progesterone (Progestogen) hypersensitivity (PH)
D1.367 - Risk factors for immediate hypersensitivity reactions to rituximab
D1.369 - Immediate hypersensitivity to dostarlimab successfully managed with desensitization
D1.370 - Desensitisation to low-dose acetylsalicylic acid in NERD. Clinical follow-up of aspirin therapy after desensitisation (ATAD)
D1.371 - Nonsteroidal anti-inflammatory drug-induced acute urticaria/angioedema: antioxidant enzymes activities and associated genetic variants
D1.373 - Hypersensitivity to Biologic Therapies: Mechanism of Cross-reactivity
D1.375 - Retrospective Analysis of Perioperative Hypersensitivity Reactions: Single-Center Experience
D1.376 - Successful Desensitization with Temozolomide in a Patient with a Hypersensitivity Reaction to Temozolomide
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download